cyclophosphamide + doxorubicin + pembrolizumab

This is a combination regimen consisting of three drugs: - Cyclophosphamide, an alkylating agent that cross-links DNA strands and inhibits DNA synthesis, leading to cell death. - Doxorubicin, an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing double-strand breaks and preventing replication. - Pembrolizumab, a monoclonal antibody immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor on T cells. By blocking PD-1 interaction with its ligands (PD-L1/PD-L2), pembrolizumab enhances T-cell-mediated anti-tumor immune responses. Cyclophosphamide plus doxorubicin is a well-established chemotherapy backbone for breast cancer and other malignancies[2][3][4]. Pembrolizumab is approved for multiple cancers as monotherapy or in combination with chemotherapy[6][8]. The triple combination is under investigation in clinical trials for various solid tumors to leverage both cytotoxic effects of chemotherapy and immunomodulatory effects of checkpoint inhibition.

Brand names

KeytrudaAdriamycinCytoxan

Other names

pembrolizumabdoxorubicincyclophosphamide